Proficient and entrepreneurial scientist with a proven success record in increasing portfolio value through the conceptualization, discovery, development, and implementation of fit-for-purpose, PD/biomarker assays used in tissue or fluid samples for patient enrollment and end-point stratification. As an ASCP-certified Molecular Biologist, I have extensive experience in the technical development and oversight of high complexity assays, with a specialty in deriving biomarkers from NGS DNA and RNA sequencing data and developing (single or multiplex, qualitative or quantitative) qPCR genotyping, RT-qPCR and dPCR assays for these targets. My work has been used for go/no-go decision making in pre-clinical/IND-tox studies, and has resulted in the generation of 3 commercial kits for radiation toxicty, and anti-PD-1 response and toxicity.